Abstract
Background: Pregnancy imposes unique physiological requirements on the mother’s thyroid gland to meet the thyroid hormone demands both for her and the fetus. A lack of consensus in current guidelines on diagnosing thyroid dysfunction during pregnancy and administering levothyroxine raises concerns regarding treatment efficacy. As hypothyroidism—subclinical or overt—is a recognized risk factor for an unfavorable pregnancy outcome, the administration of excessive or unneeded therapy can also lead to complications. Objective: This study aims to evaluate the prevalence of levothyroxine replacement therapy among euthyroid pregnant women. Materials and methods: A retrospective cohort study was conducted using the data from 6237 pregnant women who delivered at the OB/GYN Hospital “Dr. Shterev” in Sofia, Bulgaria, between January 2017 and December 2022. Thyroid function data were available for 1746 pregnant women meeting inclusion criteria: aged > 18 years, with singleton pregnancies, and thyroid hormone level tests conducted no later than mid-second trimester. Results: According to pregnancy-specific thyroid disorder diagnostic criteria, patients were categorized into euthyroid (n = 1066), subclinical hypothyroidism (n = 421), overt hypothyroidism (n = 48), isolated maternal hypothyroxinemia (n = 160), gestational thyrotoxicosis (n = 46), and Graves’ disease (n = 5). Analysis revealed that 37.7% (n = 401) of euthyroid pregnant women were prescribed levothyroxine. Only 22.9% (n = 92) of euthyroid women received hormone replacement therapy due to autoimmune thyroiditis. Conclusion: Our findings prompt consideration regarding the appropriateness of levothyroxine therapy for euthyroid pregnant women. Clear guidance is warranted on the initiation of hormone replacement therapy during pregnancy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call